Cyprus

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National

Download

Value (%)	Year	Type	Source
1.72 (1.18 - 2.49)	2015	Modelled	WHO
2.69 (2.38 - 3.04)	2013	Modelled	Schweitzer et al, 2015
0.7 (0.67 - 0.72)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
0.8 (0.77 - 0.82)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
0.81 (0.78 - 0.84)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
0.81 (0.79 - 0.84)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
0.82 (0.79 - 0.84)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
0.82 (0.80 - 0.85)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
0.83 (0.81 - 0.86)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
0.85 (0.82 - 0.88)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
0.86 (0.83 - 0.89)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
0.87 (0.84 - 0.90)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
0.89 (0.86 - 0.91)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
0.9 (0.87 - 0.93)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
0.92 (0.89 - 0.95)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
0.94 (0.91 - 0.97)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
0.96 (0.93 - 0.99)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
0.97 (0.94 - 1)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
0.99 (0.96 - 1.02)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
1.02 (0.99 - 1.05)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
1.04 (1.01 - 1.07)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
1.06 (1.03 - 1.10)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
1.08 (1.04 - 1.11)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
1.1 (1.07 - 1.14)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
1.13 (1.09 - 1.16)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
1.15 (1.11 - 1.19)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
1.17 (1.13 - 1.21)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
1.19 (1.15 - 1.23)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
1.22 (1.18 - 1.26)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
1.25 (1.21 - 1.29)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
1.28 (1.23 - 1.32)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
1.31 (1.26 - 1.36)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
0.76 (0.74 - 0.79)	2019	Modelled	IHME, GBD 2019 (accessed 2022)

Showing out of

Children under-5 years

Download

Value (%)	Year	Type	Source
0.6 (0.37 - 0.98)	2015	Modelled	WHO
0.02 (0.01 - 0.02)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
0.03 (0.02 - 0.04)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
0.03 (0.02 - 0.04)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
0.03 (0.02 - 0.04)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
0.03 (0.02 - 0.04)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
0.03 (0.02 - 0.04)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
0.03 (0.02 - 0.04)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
0.03 (0.03 - 0.04)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
0.04 (0.03 - 0.04)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
0.04 (0.03 - 0.05)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
0.04 (0.03 - 0.05)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
0.05 (0.04 - 0.06)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
0.05 (0.04 - 0.06)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
0.06 (0.05 - 0.07)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
0.07 (0.05 - 0.08)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
0.07 (0.06 - 0.09)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
0.08 (0.06 - 0.09)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
0.08 (0.06 - 0.10)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
0.08 (0.07 - 0.10)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
0.09 (0.07 - 0.11)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
0.1 (0.08 - 0.12)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
0.11 (0.09 - 0.13)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
0.12 (0.10 - 0.14)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
0.14 (0.11 - 0.17)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
0.16 (0.13 - 0.19)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
0.18 (0.14 - 0.22)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
0.21 (0.17 - 0.25)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
0.24 (0.20 - 0.29)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
0.28 (0.23 - 0.34)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
0.32 (0.27 - 0.39)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
0.37 (0.30 - 0.46)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
0.34 (0.26 - 0.45)	2020	Modelled	WHO

Showing out of

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
5.6	2017	Survey/reported	ECDC
1.53	2016	Survey/reported	EMCDDA
5	2015	Survey/reported	EMCDDA
0.91	2014	Survey/reported	EMCDDA
6.09	2013	Survey/reported	EMCDDA
2.38	2012	Survey/reported	EMCDDA
0.66	2011	Survey/reported	EMCDDA
1.71	2010	Survey/reported	EMCDDA
0.87	2009	Survey/reported	EMCDDA
7.84	2007	Survey/reported	EMCDDA
2.08	2006	Survey/reported	EMCDDA
3.06	2004	Survey/reported	EMCDDA

Showing out of

People who have ever injected drugs (PWID)

Download

Value (%)	Year	Type	Source
5.6	2017	Survey/reported	EMCDDA

Technical notes

Number of people living with chronic HBV

National

Download

Value	Year	Type	Source
9,158 (8,842 - 9,457)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
9,525 (9,185 - 9,853)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
9,761 (9,431 - 10,078)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
9,789 (9,456 - 10,120)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
9,653 (9,346 - 9,961)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
9,531 (9,222 - 9,851)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
9,449 (9,139 - 9,749)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
9,408 (9,091 - 9,706)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
9,381 (9,066 - 9,675)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
9,340 (9,021 - 9,640)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
9,262 (8,926 - 9,577)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
9,185 (8,874 - 9,472)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
9,147 (8,843 - 9,429)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
9,128 (8,844 - 9,397)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
9,105 (8,824 - 9,384)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
9,060 (8,779 - 9,351)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
9,026 (8,753 - 9,302)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
9,034 (8,763 - 9,296)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
9,063 (8,786 - 9,322)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
9,092 (8,809 - 9,370)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
9,102 (8,798 - 9,392)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
9,117 (8,818 - 9,390)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
9,161 (8,857 - 9,425)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
9,215 (8,915 - 9,481)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
9,258 (8,958 - 9,538)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
9,275 (8,976 - 9,572)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
9,291 (8,984 - 9,576)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
9,333 (9,028 - 9,614)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
9,391 (9,084 - 9,674)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
9,457 (9,135 - 9,755)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
9,521 (9,191 - 9,836)	1990	Modelled	IHME, GBD 2019 (accessed 2022)

Showing out of

HBV-related death rate

National

Download

Value (per 100,000)	Year	Type	Source
1.23 (0.92 - 1.61)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
1.96 (1.39 - 2.80)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
1.92 (1.34 - 2.69)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
1.94 (1.36 - 2.75)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
1.96 (1.39 - 2.77)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
1.93 (1.39 - 2.72)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
1.92 (1.40 - 2.67)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
1.87 (1.39 - 2.55)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
1.79 (1.33 - 2.45)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
1.7 (1.27 - 2.31)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
1.6 (1.19 - 2.16)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
1.51 (1.13 - 2.03)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
1.43 (1.08 - 1.90)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
1.38 (1.04 - 1.81)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
1.32 (1 - 1.73)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
1.26 (0.96 - 1.64)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
1.28 (0.98 - 1.67)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
1.27 (0.97 - 1.67)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
1.24 (0.96 - 1.63)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
1.22 (0.94 - 1.58)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
1.21 (0.93 - 1.58)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
1.2 (0.93 - 1.56)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
1.18 (0.92 - 1.53)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
1.18 (0.91 - 1.52)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
1.2 (0.93 - 1.55)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
1.19 (0.92 - 1.54)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
1.21 (0.93 - 1.56)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
1.2 (0.92 - 1.57)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
1.2 (0.92 - 1.56)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
1.22 (0.92 - 1.59)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
1.23 (0.92 - 1.61)	2019	Modelled	IHME, GBD 2019 (accessed 2022)

Showing out of

Technical notes

HBV-related deaths

National

Download

Value	Year	Type	Source
48	2016	Modelled	WHO
15 (10 - 21)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
16 (11 - 23)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
15 (11 - 22)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 23)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
16 (11 - 23)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 23)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 22)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
14 (11 - 20)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 21)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
15 (11 - 21)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
14 (10 - 19)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 18)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 17)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
13 (10 - 18)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
14 (10 - 18)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
14 (11 - 18)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
14 (11 - 18)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
15 (11 - 19)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
15 (11 - 19)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
15 (12 - 20)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
15 (12 - 20)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 21)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 21)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
16 (12 - 21)	2019	Modelled	IHME, GBD 2019 (accessed 2020)

Showing out of

Technical notes

Percent of liver cancer deaths attributable to HBV

National

Download

Value (%)	Year	Type	Source
7 (4 - 10)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
6 (4 - 9)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
7 (5 - 10)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
7 (5 - 10)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
7 (4 - 9)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
7 (5 - 11)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
8 (5 - 11)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
8 (5 - 12)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
8 (5 - 12)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
9 (6 - 12)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
8 (6 - 12)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
9 (6 - 12)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
9 (6 - 12)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
9 (6 - 12)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
9 (6 - 13)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
9 (6 - 12)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
8 (6 - 12)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
11 (8 - 17)	2019	Modelled	IHME, GBD 2019 (accessed 2020)

Showing out of

Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants

Download

Value (%)	Year	Type	Source
94	2019	Survey/reported	WHO/UNICEF
94	2021	Survey/reported	WHO/UNICEF

Showing out of

Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)

Download

Value	Year	Type	Source
1	2017	Survey/reported	EMCDDA, 2019
0 (0 - 0)	2015	Survey/reported	EMCDDA, 2017
1	2017	Survey/reported	ECDC

Showing out of

Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
18	2017	Survey/reported	EMCDDA, 2019

HBV National Action Plan

Source;

HBV elimination goal

Source:

Year of HBV elimination goal

2030

Source:

HBV testing policy

No policy

Source:

HepB birth dose policy

Source: WHO

Eligible for HBV generic medicines

Source: MPP

HCV National Action Plan

Source:

HCV elimination goal

Source:

Year of HCV elimination goal

2030

Source:

HCV testing policy

No policy

Source:

Eligible for HCV generic medicines

Source: MPP

At least one needle-syringe exchange program (NSP) operational

Yes

Source: Harm Reduction International

At least one opioid substitution therapy (OST) program operational

Yes

Source: Harm Reduction International

NSP in at least one prison

Source: Harm Reduction International

OST in at least one prison

Yes

Source: Harm Reduction International

% of substance use disorder facilities offering hepatitis testing

Some (11-30%)

Source: WHO

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National

Download

Value (%)	Year	Type	Source
0.69 (0.56 - 0.84)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
0.68 (0.56 - 0.84)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
0.68 (0.55 - 0.84)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
0.66 (0.54 - 0.82)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.80)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.80)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.80)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.80)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.80)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.80)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
0.63 (0.52 - 0.77)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
0.6 (0.50 - 0.73)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
0.57 (0.47 - 0.69)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
0.54 (0.45 - 0.65)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
0.53 (0.43 - 0.64)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.43 - 0.63)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.42 - 0.63)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.42 - 0.63)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
0.52 (0.42 - 0.63)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
0.53 (0.43 - 0.64)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
0.55 (0.45 - 0.67)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
0.58 (0.47 - 0.70)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
0.61 (0.50 - 0.75)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
0.65 (0.53 - 0.81)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
0.64 (0.52 - 0.79)	2019	Modelled	IHME, GBD 2019 (accessed 2020)

Showing out of

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
43.28	2016	Survey/reported	EMCDDA
44.2	2015	Survey/reported	EMCDDA
43.11	2014	Survey/reported	EMCDDA
47.56	2013	Survey/reported	EMCDDA
55.42	2012	Survey/reported	EMCDDA
52.63	2011	Survey/reported	EMCDDA
51.28	2010	Survey/reported	EMCDDA
46.55	2009	Survey/reported	EMCDDA
29.21	2008	Survey/reported	EMCDDA
34.31	2007	Survey/reported	EMCDDA
29.59	2006	Survey/reported	EMCDDA
50	2008	Survey/reported	EMCDDA; Demetriou V. L., Van de Vijver D. A., Hezka J., Georgiades N., Savvopoulou N., Charilaou C. C., Argyriou A., Pavlou T., Platritis K., Veresies K., Kostrikis L. , 2009
9.1	2004	Survey/reported	EMCDDA

Showing out of

Women of childbearing age (15–49 years)

Download

Value (%)	Year	Type	Source
0.26 (0.21 - 0.36)	2019	Modelled	Dugan et al., 2021

Technical notes

Prevalence of anti-HCV

National

Download

Value (%)	Year	Type	Source
0.6 (0.50 - 1.90)	2014	Survey/reported	Gower et al, 2014

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
49.7 (44.40 - 55)	2014	Modelled	Degenhardt L et al, 2017
47.6 (36.40 - 58.90)	2013	Survey/reported	EMCDDA
56.6	2017	Survey/reported	ECDC

Showing out of

People who have ever injected drugs (PWID)

Download

Value (%)	Year	Type	Source
56.6	2017	Survey/reported	EMCDDA

Technical notes

Number of people living with chronic HCV (RNA+/cAg)

National

Download

Value	Year	Type	Source
4,731 (3,842 - 5,884)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
4,532 (3,690 - 5,597)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
4,344 (3,534 - 5,281)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
4,192 (3,422 - 5,080)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
4,103 (3,365 - 4,991)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
4,107 (3,340 - 4,994)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
4,171 (3,400 - 5,046)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
4,242 (3,460 - 5,127)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
4,318 (3,537 - 5,211)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
4,397 (3,608 - 5,323)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
4,483 (3,684 - 5,397)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
4,571 (3,756 - 5,502)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
4,660 (3,828 - 5,602)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
4,757 (3,908 - 5,755)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
4,866 (3,996 - 5,893)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
4,993 (4,101 - 6,048)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
5,236 (4,331 - 6,329)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
5,637 (4,656 - 6,835)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
6,107 (5,030 - 7,444)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
6,550 (5,364 - 8,013)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
6,857 (5,581 - 8,425)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
7,034 (5,741 - 8,663)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
7,180 (5,888 - 8,846)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
7,313 (5,973 - 8,996)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
7,452 (6,081 - 9,153)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
7,618 (6,201 - 9,361)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
7,905 (6,469 - 9,740)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
8,204 (6,673 - 10,142)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
8,404 (6,868 - 10,294)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
8,468 (6,863 - 10,372)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
8,558 (6,946 - 10,468)	2019	Modelled	IHME, GBD 2019 (accessed 2022)

Showing out of

Women of childbearing age (15–49 years)

Download

Value	Year	Type	Source
790 (640 - 1,100)	2019	Modelled	Dugan et al., 2021

HCV-related death rate

National

Download

Value (Deaths per 100,000)	Year	Type	Source
3.79 (3 - 4.72)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
3.53 (2.54 - 4.72)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
3.45 (2.46 - 4.58)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
3.49 (2.49 - 4.66)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
3.52 (2.57 - 4.67)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
3.46 (2.56 - 4.53)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
3.43 (2.58 - 4.51)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
3.41 (2.56 - 4.46)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
3.4 (2.58 - 4.45)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
3.42 (2.61 - 4.46)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
3.42 (2.63 - 4.45)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
3.38 (2.62 - 4.40)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
3.34 (2.62 - 4.29)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
3.33 (2.62 - 4.27)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
3.3 (2.59 - 4.22)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
3.31 (2.63 - 4.20)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
3.43 (2.69 - 4.31)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
3.38 (2.67 - 4.26)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
3.45 (2.73 - 4.35)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
3.45 (2.75 - 4.33)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
3.46 (2.76 - 4.32)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
3.5 (2.80 - 4.34)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
3.58 (2.87 - 4.41)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
3.5 (2.82 - 4.32)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
3.52 (2.82 - 4.31)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
3.62 (2.90 - 4.50)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
3.67 (2.95 - 4.56)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
3.67 (2.91 - 4.53)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
3.67 (2.92 - 4.54)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
3.73 (2.93 - 4.62)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
3.79 (3 - 4.72)	2019	Modelled	IHME, GBD 2019 (accessed 2022)

Showing out of

Technical notes

HCV-related deaths

National

Download

Value	Year	Type	Source
38	2016	Modelled	WHO
50 (39 - 62)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
50 (39 - 62)	2019	Modelled	IHME, GBD 2019 (accessed 2020)
48 (38 - 60)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
47 (37 - 58)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
46 (37 - 57)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
45 (36 - 56)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
44 (35 - 54)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
43 (34 - 53)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
41 (33 - 50)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
40 (32 - 49)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
39 (31 - 49)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
38 (30 - 47)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
37 (30 - 47)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
36 (29 - 46)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
35 (28 - 44)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
34 (27 - 43)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
33 (26 - 42)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
32 (25 - 41)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
32 (25 - 41)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
31 (24 - 40)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
31 (24 - 40)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
31 (24 - 40)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
30 (23 - 40)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
30 (23 - 39)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
29 (22 - 38)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
29 (22 - 38)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
29 (21 - 38)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
29 (21 - 38)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
29 (20 - 38)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
28 (20 - 37)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
27 (19 - 36)	1990	Modelled	IHME, GBD 2019 (accessed 2022)

Showing out of

Technical notes

Percent of liver cancer deaths attributable to HCV

National

Download

Value (%)	Year	Type	Source
17 (12 - 23)	1990	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 23)	1991	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 23)	1992	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1993	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1994	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1995	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1996	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1997	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1999	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 22)	1998	Modelled	IHME, GBD 2019 (accessed 2022)
17 (12 - 23)	2000	Modelled	IHME, GBD 2019 (accessed 2022)
18 (13 - 23)	2001	Modelled	IHME, GBD 2019 (accessed 2022)
18 (13 - 24)	2002	Modelled	IHME, GBD 2019 (accessed 2022)
19 (14 - 25)	2004	Modelled	IHME, GBD 2019 (accessed 2022)
19 (14 - 24)	2003	Modelled	IHME, GBD 2019 (accessed 2022)
21 (15 - 27)	2006	Modelled	IHME, GBD 2019 (accessed 2022)
20 (14 - 26)	2005	Modelled	IHME, GBD 2019 (accessed 2022)
24 (17 - 30)	2008	Modelled	IHME, GBD 2019 (accessed 2022)
22 (16 - 29)	2007	Modelled	IHME, GBD 2019 (accessed 2022)
25 (18 - 32)	2009	Modelled	IHME, GBD 2019 (accessed 2022)
26 (19 - 33)	2010	Modelled	IHME, GBD 2019 (accessed 2022)
29 (22 - 37)	2013	Modelled	IHME, GBD 2019 (accessed 2022)
27 (20 - 35)	2011	Modelled	IHME, GBD 2019 (accessed 2022)
28 (21 - 36)	2012	Modelled	IHME, GBD 2019 (accessed 2022)
29 (22 - 38)	2014	Modelled	IHME, GBD 2019 (accessed 2022)
30 (22 - 38)	2015	Modelled	IHME, GBD 2019 (accessed 2022)
30 (23 - 39)	2016	Modelled	IHME, GBD 2019 (accessed 2022)
30 (22 - 38)	2017	Modelled	IHME, GBD 2019 (accessed 2022)
30 (22 - 38)	2018	Modelled	IHME, GBD 2019 (accessed 2022)
30 (22 - 38)	2019	Modelled	IHME, GBD 2019 (accessed 2022)
40 (30 - 50)	2019	Modelled	IHME, GBD 2019 (accessed 2020)

Showing out of

Technical notes

Number of needles/syringes per PWID per year

People who inject drugs (PWID)

Download

Value	Year	Type	Source
1	2017	Survey/reported	EMCDDA, 2019
0 (0 - 0)	2015	Survey/reported	EMCDDA, 2017
1	2017	Survey/reported	ECDC

Showing out of

Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)

Download

Value (%)	Year	Type	Source
18	2017	Survey/reported	EMCDDA, 2019

HBV National Action Plan

Source;

HBV elimination goal

Source:

Year of HBV elimination goal

2030

Source:

HBV testing policy

No policy

Source:

HepB birth dose policy

Source: WHO

Eligible for HBV generic medicines

Source: MPP

HCV National Action Plan

Source:

HCV elimination goal

Source:

Year of HCV elimination goal

2030

Source:

HCV testing policy

No policy

Source:

Eligible for HCV generic medicines

Source: MPP

At least one needle-syringe exchange program (NSP) operational

Yes

Source: Harm Reduction International

At least one opioid substitution therapy (OST) program operational

Yes

Source: Harm Reduction International

NSP in at least one prison

Source: Harm Reduction International

OST in at least one prison

Yes

Source: Harm Reduction International

% of substance use disorder facilities offering hepatitis testing

Some (11-30%)

Source: WHO

Overview

HBV elimination goal

Year of goal

2030

HCV elimination goal

Year of goal

2030

Prevalence (national)

Modelled

IHME, GBD 2019 (accessed 2022)

IHME, GBD 2019 (accessed 2020)

Survey/surveillance

No data available

Hepatitis related deaths (national)

Modelled

HBV

2019

(12 - 21)

IHME, GBD 2019 (accessed 2020)

Survey/surveillance

No data available

HBV chart

Modelled

HCV

2019

(39 - 62)

IHME, GBD 2019 (accessed 2022)

Survey/surveillance

No data available

HCV chart

Prevalence < 5

HBV

0.34 (%)

2020, latest modelled

(0.26 - 0.45(%))

WHO

Prevalence PWID

HCV

56.60 (%)

2017, survey/surveillance

ECDC

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

HCV

2017

EMCDDA, 2019

Eligible for HBV generic medicines

Eligible for HCV generic medicines

Latest news

A new partnership in the fight against hepatitis: ELPA and the Coalition join forces

23 Apr 2021

Announcements

View all

Action plan

National Strategy to Eliminate Viral Hepatitis in Cyprus 2019-2024

2018

Republic of Cyprus Ministry of Health

View all

Elimination champion

Dr. Petros Katsioloudes (2019)

Over 3 years, he involved all stakeholders, especially the patients in Cyprus to receive Ministry approval for a National Action Plan for Eradication of Hepatitis C 2019-2024.